All In Biotech

Drug Trial Radar · NCT01717326

A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)

A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen MK-5172 and MK-8742 ± Ribavirin (RBV) in Subjects With Chronic Hepatitis C Virus Infection

Last checked: Nov 19, 2026Latest source record: Feb 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 573 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

573

Actual

Start

Feb 7, 2013

Primary completion

Feb 23, 2015

Study completion May 6, 2015

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 30, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study of the safety and efficacy of grazoprevir (MK-5172) in combination with elbasvir (MK-8742) ± ribavirin (RBV). The primary efficacy endpoint will be Sustained Virologic Response 12 weeks after the end of all study therapy (SVR12) in each of the treatment arms.

Conditions

  • Hepatitis C

Interventions

  • GrazoprevirDrug

    100 mg tablet orally QD

  • ElbasvirDrug

    Part A: 20 or 50 mg capsule orally QD Parts B, C, and D: 50 mg capsule orally QD

  • Placebo to ElbasvirDrug

    Placebo to Elbasvir 20 or 50 mg capsule, orally, once daily for 12 weeks to maintain blind (Part A only)

  • RibavirinDrug

    Oral capsules BID at a total daily dose from 800 to 1400 mg based on participant weight

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After the End of All Study Therapy (SVR12)Time frame: 12 weeks after end of therapy (up to 30 weeks)
  2. Percentage of Participants Experiencing at Least One Adverse Event (AE) During the Treatment Period and First 14 Follow-up DaysTime frame: From Day 1 [post-dose] through 14 days following last dose of study drug (up to 20 weeks)
  3. Percentage of Participants Discontinuing Study Therapy Due to an AE During the Treatment Period and First 14 Follow-up DaysTime frame: From Day 1 [post-dose] through 14 days following last dose of study drug (up to 20 weeks)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.